Advisory - Pfizer Canada recalls two lots of EpiPen / EpiPen Jr auto-injectors (0.3 mg and 0.15 mg epinephrine) due to possible device failure
OTTAWA, April 1, 2017 /CNW/ -
Issue Pfizer Canada, in consultation with Health Canada, is voluntarily recalling one lot of EpiPen auto-injector and one lot of EpiPen Jr. auto-injector. The recalled devices may contain a defective part that may result in the auto-injector failing to activate or requiring increased force to activate.
This recall is being conducted following two confirmed international reports of the device failing to activate. There have been no confirmed reports of device failures involving lots distributed in Canada.
EpiPen/EpiPen Jr. auto-injectors are used to deliver an emergency treatment of adrenaline (epinephrine) to patients who are at risk or have a history of serious allergic reactions (anaphylaxis). Failure of the auto-injector to activate may result in patients not receiving the required dose of adrenaline (epinephrine), resulting in the worsening of symptoms of anaphylaxis or anaphylactic reactions, which could be life threatening.
Affected products
EpiPen (0.3 mg epinephrine) auto-injector lot 5GU763, expiry date May 2017, 67844 units distributed in Canada
EpiPen Jr (0.15 mg epinephrine) auto-injector lot 5GR765, expiry date March 2017, 39503 units distributed in Canada
Who is affected
Patients and caregivers who have the affected device
What consumers should do
Patients and caregivers should check whether they have the affected device.
Contact your pharmacy to arrange return of your EpiPen/EpiPen Jr. device and obtain a replacement as soon as possible.
Pfizer Canada is also advising patients and caregivers to keep the affected EpiPen/EpiPen Jr. auto-injectors until a replacement is obtained.
In the event that a life-threatening allergic reaction (anaphylaxis) occurs before you can obtain a replacement, use your EpiPen/EpiPen Jr. product as directed by your healthcare provider and then seek emergency medical attention.
Speak with your healthcare professional if you are concerned about your health.
Contact Pfizer Canada at 1-866-9Pfizer (1-866-973-4937) or [email protected] for more information on the recall.
Report adverse events to health products to Health Canada by calling toll-free at 1?866?234?2345, or by reporting online, by mail or by fax.
Report complaints about health products to Health Canada by calling toll-free at 1?800?267?9675, or complete an online complaint form.
What Health Canada is doing Health Canada is monitoring the company's recall. If new safety information is identified, Health Canada will take appropriate action and inform Canadians.
For more information Stay connected with Health Canada and receive the latest advisories and product recalls using social media tools.
The global gastroesophageal reflux disease (GERD) market size is estimated to grow by USD 879.8 million from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of 3.2% during the forecast period. Rising geriatric...
Pendopharm, a division of Pharmascience Inc., announced today that it has signed an exclusive distribution agreement with Ascendis Pharma A/S ("Ascendis"), a global biopharmaceutical company headquartered in Copenhagen, Denmark. Under the terms of...
Imperial Tobacco Canada Limited ("ITCAN") has officially submitted its feedback to Health Canada regarding the proposed Ministerial Order on nicotine replacement therapy products (NRTs). ITCAN strongly believes that NRTs, especially innovative...
The "Regenerative Medicine Collaboration and Licensing Deals 2016-2024" report has been added to ResearchAndMarkets.com's offering.
Regenerative Medicine Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented...
The "Diagnostic Imaging Collaboration and Licensing Deals 2016-2024" report has been added to ResearchAndMarkets.com's offering.
Diagnostic Imaging Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to...
King Faisal Specialist Hospital & Research Centre (KFSH&RC) has achieved a significant milestone in its Robotic Cardiac Surgery Program, which was initiated in February 2019. Within its first year, the program performed 105 cardiac procedures. As of...